Prime Medicine, Inc. (PRME) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Join SI Premium – FREE
Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.46), $0.03 better than the analyst estimate of ($0.49).
For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Prime Medicine (PRME) at Outperform
- TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
- Benchmark Reiterates Hold Rating on iQIYI (IQ) Following Q2 Earnings, Revenue Miss
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
